Bunkerhill Health vs Tempus AI Imaging

Tempus Pixel started as Arterys, which Tempus bought in October 2022. It segments and measures lesions on CT and MR, tracks them over time, produces RECIST-style response reports and analyses cardiac MR. The September 2025 510(k), K252539, covers the updated Pixel device, whose update generates T1 and T2 inline maps from raw MRI data. Pixel Lung's clearance (K203744) is not indicated for nodule detection, so US lung nodule detection comes from a third-party engine, as do the breast and prostate components. That counts against Pixel for a buyer who wants one vendor's own algorithms across organs. The studies Tempus footnotes concern those third-party engines or the research tool, not necessarily current Pixel. An oncology service tracking response across CT and MR fits Tempus, and the vendor says it integrates with PACS, EHR, worklist and dictation systems without naming any. Bunkerhill answers a separate question for health systems. It is an AI agent platform with nine cleared imaging algorithms, osteoporosis detection from prior CTs among its use cases, and a demo request instead of a price.